369 related articles for article (PubMed ID: 17967591)
1. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Feldman AM; Oren RM; Abraham WT; Boehmer JP; Carson PE; Eichhorn E; Gilbert EM; Kao A; Leier CV; Lowes BD; Mathier MA; McGrew FA; Metra M; Zisman LS; Shakar SF; Krueger SK; Robertson AD; White BG; Gerber MJ; Wold GE; Bristow MR;
Am Heart J; 2007 Nov; 154(5):861-9. PubMed ID: 17967591
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the enoximone clinical trials program.
Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
[TBL] [Abstract][Full Text] [Related]
3. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
[TBL] [Abstract][Full Text] [Related]
5. Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors.
Lee HR; Hershberger RE; Port JD; Rasmussen R; Renlund DG; O'Connell JB; Gilbert EM; Mealey PC; Volkman K; Menlove R
J Thorac Cardiovasc Surg; 1991 Aug; 102(2):246-58. PubMed ID: 1650867
[TBL] [Abstract][Full Text] [Related]
6. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Weber KT; Janicki JS; Jain MC
J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
[TBL] [Abstract][Full Text] [Related]
7. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.
Metra M; Eichhorn E; Abraham WT; Linseman J; Böhm M; Corbalan R; DeMets D; De Marco T; Elkayam U; Gerber M; Komajda M; Liu P; Mareev V; Perrone SV; Poole-Wilson P; Roecker E; Stewart J; Swedberg K; Tendera M; Wiens B; Bristow MR;
Eur Heart J; 2009 Dec; 30(24):3015-26. PubMed ID: 19700774
[TBL] [Abstract][Full Text] [Related]
8. [Clinico-pharmacologic aspects of therapy with enoximone].
Trenk D; Jähnchen E
Z Kardiol; 1994; 83 Suppl 2():7-14. PubMed ID: 8091828
[TBL] [Abstract][Full Text] [Related]
9. [Use of enoximone in patients with acute and subacute heart failure in the intensive care unit].
Holubarsch C; Pieske B; Hasenfuss G; Just H
Z Kardiol; 1994; 83 Suppl 2():21-5. PubMed ID: 8091821
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of new cardiac agents using differential therapeutic criteria].
Redmann K; Lunkenheimer PP; Rettig G; Isringhaus H; Flameng W; Demeyere R
Z Kardiol; 1991; 80 Suppl 4():7-14. PubMed ID: 1833902
[TBL] [Abstract][Full Text] [Related]
12. Outpatient inotropic therapy in heart transplant candidates: should its use influence waiting list priority status?
Winkel E; Kao W; Fisher SG; Heroux AL; Johnson MR; Costanzo MR
J Heart Lung Transplant; 1998 Aug; 17(8):809-16. PubMed ID: 9730431
[TBL] [Abstract][Full Text] [Related]
13. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Kurien S; Warfield KT; Wood CM; Miller WL
Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
[TBL] [Abstract][Full Text] [Related]
14. [Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone].
Holubarsch C; Hasenfuss G; Thierfelder L; Heiss HW; Just H
Z Kardiol; 1991; 80 Suppl 4():35-40. PubMed ID: 1833895
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
16. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.
Masutani S; Cheng HJ; Hyttilä-Hopponen M; Levijoki J; Heikkilä A; Vuorela A; Little WC; Cheng CP
J Pharmacol Exp Ther; 2008 Apr; 325(1):236-47. PubMed ID: 18174383
[TBL] [Abstract][Full Text] [Related]
17. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Shakar SF; Abraham WT; Gilbert EM; Robertson AD; Lowes BD; Zisman LS; Ferguson DA; Bristow MR
J Am Coll Cardiol; 1998 May; 31(6):1336-40. PubMed ID: 9581729
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
[TBL] [Abstract][Full Text] [Related]
19. Chronic therapy of severe heart failure with enoximone.
Gilfrich HJ; Witzke-Gross J; Römer A
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S75-7. PubMed ID: 2480490
[TBL] [Abstract][Full Text] [Related]
20. [Effect of oral administration of enoximone on cardiac performance, arterial circulation at rest and on the vasoconstrictor effect of local noradrenaline infusions into the human hand vein].
Breithaupt K; Belz GG; Kempinski S; Schicketanz KH; Dieterich HA
Z Kardiol; 1991; 80 Suppl 4():15-20. PubMed ID: 1833892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
